

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PATENT  
1718-0214P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Johan HARMENBERG et al. Conf.:  
Appl. No.: 10/771,259 Group:  
Filed: February 2, 2004 Examiner:  
For: PHARMACEUTICAL COMBINATION

LETTER

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

March 24, 2004

Sir:

On March 2, 2004, Applicants submitted an Information Disclosure Statement listing the new references that have come to light and that formed the basis for the Applicants request for Reissue Examination. These references are:

- LEVIN; US 4,942,031; July 17, 1990
- LEVIN; US 5,023,090; June 11, 1991
- LEVIN; US 5,656,301; August 12, 1997
- F.Y. AOKI et al., "Topical glucocorticoid alone or combined with 10% acyclovir...", XP 001117608. Abstract and Clarified Text.

Applicants wish to point out to the Examiner that the references Power and MCGILL were inadvertently included on the IDS PTO 1449 Form. Applicants wish to point out that these references were submitted to the USPTO during the prosecution of

the original application. The Examiner handling the case at the time fully considered this reference as can be seen by its presence in the "References Cited" section on page 1 of the issued patent. We have enclosed a copy for your review.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Leonard R. Svensson (Reg. No. 30,330) at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on: 03-24-2004  
(Date of Deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Sander B. Paulo  
(Signature)  
March 24, 2004  
(Date of Signature)

LRS/SWG/sbp  
1718-0214P

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By [Signature] #47,604  
for Leonard R. Svensson, #30,330  
P.O. Box 747  
Falls Church, VA 22040-0747  
(714) 708-8555

Attachment(s): Copy of Page 1 of US 6,337,324

(Rev. 02/12/2004)



US 6,337,324 B1

**(12) United States Patent**  
**Harmenberg et al.****(10) Patent No.: US 6,337,324 B1****(45) Date of Patent: \*Jan. 8, 2002****(54) PHARMACEUTICAL COMBINATION****(75) Inventors:** Johan Georg Harmenberg, Stockholm;  
Ann Harriet Margareta Kristofferson,  
Södertälje, both of (SE)**(73) Assignee:** Medivir, AB, Huddinge (SE)**(\*) Notice:** This patent issued on a continued prosecution application filed under 37 CFR 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. 154(a)(2).

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

**(21) Appl. No.:** 08/612,847**(22) PCT Filed:** Feb. 2, 1996**(86) PCT No.:** PCT/SE96/00124

§ 371 Datē: Mār. 8, 1996

§ 102(e) Date: Mar. 8, 1996

**(87) PCT Pub. No.:** WO96/24355

PCT Pub. Date: Aug. 15, 1996

**(30) Foreign Application Priority Data**

Feb. 6, 1995 (WO) ..... PCT/SE95/00114

**(51) Int. Cl.<sup>7</sup>** ..... A61K 31/56**(52) U.S. Cl.** ..... 514/171; 514/75; 514/81;  
514/82; 514/85; 514/120; 514/179**(58) Field of Search** ..... 514/179, 171,  
514/75; 518/85, 81, 82, 120**(56) References Cited****U.S. PATENT DOCUMENTS**

3,317,384 A	5/1967	Underwood	167/58
4,512,978 A	4/1985	Inwood	424/145
4,610,868 A	9/1986	Fountain et al.	424/1.1
6,068,860 A *	5/2000	Carlsson et al.	424/601

**FOREIGN PATENT DOCUMENTS**

AU	0636255	*	5/1992	.....	A61K/31/66
AU	636255		4/1993	.....	A61K/31/66
EP	0350287		1/1990	.....	A61K/31/70
EP	0594223		4/1994	.....	A61K/31/70
WO	9219244		11/1992	.....	A61K/31/57
WO	9503805		2/1995	.....	A61K/31/52
WO	9527501		10/1995	.....	A61K/38/21

**OTHER PUBLICATIONS**

Alenius, S., et al; Therapeutic Effects of Foscarnet Sodium and Acyclovir on Cutaneous Infections due to Herpes Simplex Virus Type 1 in Guinea Pigs, J. Inf. Dis. 1982; 145:569-73.

The Human Herpesviruses, ed. Roizman et al. 1993, Whitely, Richard et al.; The epidemiology and Clinical Manifestations of Herpes Simplex Virus Infections.

Kristofferson, A. et al.; Limited Efficacy of Inhibitors of Herpes Simplex Virus DNA Synthesis in Murine Models of Recrudescence Disease, J. Gen. Virol. (1988), 69, 1157-1166.

Schinazi, R.F. et al; Studies In Vitro and In Vivo of Combinations of Antivirals and Antiinflammatory Agents in Relation to the Treatment of Herpes Simplex Viruses, Current Chemotherapy and Immunotherapy, 12th Int. Congress, Florence, Jul. 1981.

From Chemical Abstracts, vol. 112, nr. CA:125021: Loftson, T.; Effect of choline esters and oleic acid on the penetration of acyclovir, estradiol, hydrocortisone, nitroglycerin, retinoic acid and trifluorothymidine across hairless mouse skin in vitro, Acta Pharm. Nor. (1989), 1(5), 279-86.

From Chemical Abstracts, vol. 112, nr 4, (dissertation): Choi, Hoo Kyun: Enhanced transdermal delivery of propanolol, hydrocortisone, acyclovir and peptide-type drugs (1989).

Power, W J et al., Acyclovir ointment plus topical betamethasone or placebo in first episode disciform keratitis, British Journal of Ophthalmology 1992; 76:711-713.

McGill, J. Herpes zoster ocular infection, Scand. J. Infect. Dis. Suppl. 46: 85-88, 1985.

ABPI Compendium of Data Sheets and Summaries of Product Characteristics, 1996-97, Datapharm Publications Ltd., pp. 390 and 1271.

Berkow, et al., The Merck Manual of Diagnosis and Therapy, 14<sup>th</sup> Edition, pp. 2023-2025 (1982).

Chemical Abstract No. 97: 156002r from Schinazi, et al., Curr. Chemother. Immunother. 2, 1085-1087 (1982).\*

Merck Index 10th Ed #140, #4135, #1435, 1984.\*

Notter et al, 89 CA:157769t, 1978.\*#f139##

**Primary Examiner**—Frederick Krass**(74) Attorney, Agent, or Firm**—White & Case LLP**(57)****ABSTRACT**

The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.

**36 Claims, 3 Drawing Sheets**